Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Dialysis Clinic, Inc. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to evaluate if formoterol fumarate is effective in treating patients with diabetic kidney disease. Study participants will be randomly assigned to either receive formoterol fumarate (in addition to their current standard of care treatment) or standard of care treatment only. Study participants will have a 50% chance of receiving formoterol fumarate and a 50% chance of not receiving formoterol fumarate. Both groups will continue their standard of care treatment during the study. The primary goal is to gather data on feasibility and effect sizes to properly power a future clinical trial.
Glomerular function is highly dependent on specialized cells known as podocytes, which are critical components of glomeruli. Diseases affecting podocytes and the glomerulus, such as diabetes, are the leading causes of ESKD, and there are no specific therapies that restore injury-induced loss of podocyte structure and function. It was previously shown using mouse models of podocyte injury that formoterol fumarate, a long-acting β2-AR agonist given four hours following injury, when glomerular dysfunction is already established, restored glomerular structure, significantly reduced proteinuria, and accelerated recovery of glomerular function. To determine if a similar effect occurred in CKD, specifically DN, investigators used streptozotocin, a murine model of type 1 diabetes, and a high fat diet (HFD), a murine model of type 2 diabetes, to examine the role of formoterol fumarate in DN. Following formoterol fumarate treatment, there was a marked recovery from and reversal of DN in the streptozotocin and HFD mice treated with formoterol fumarate compared to those treated with vehicle alone at the ultrastructural, histological, and functional levels. Investigators also performed a competing risk regression in Veterans aged 65 or over with incident CKD stage 4 to compare the rate of ESKD progression in Veterans without and with COPD, who use β2-AR agonists. Investigators found a 25.6% reduction in the rate of ESKD in Veterans with COPD compared to those without4. In a second cohort of Veterans, Investigators demonstrated significantly slower progression from CKD stage 3 to CKD stage 5 in patients with COPD compared to those without COPD. Together these data indicate that β2-AR agonists, especially formoterol fumarate, may be a novel treatment for DN.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Standard of Care Only | No Intervention | Standard of Care Treatment Only | |
| Formoterol Fumarate + Standard of Care Treatment | Experimental | Formoterol Fumarate Inhalation Solution as one 20 mcg unit-dose vial administered twice daily (morning and evening) by nebulization (in addition to standard of care treatment) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Formoterol furmarate (20 μg) | Drug | Investigators chose to use the long-acting β2-AR agonist, formoterol, because of its efficacy and safety profile in patients with COPD and because formoterol showed the most association with protection from progression of CKD in our retrospective study. |
| Measure | Description | Time Frame |
|---|---|---|
| Feasibility: refusal rate and adherence during the 36-week treatment | The primary measures of feasibility will be study refusal rate and adherence during the 36-week treatment. Refusal rate will be the percentage of individuals who are offered the opportunity to enroll but choose not to accept it. Adherence will be defined as the proportion of doses taken during the 36-week treatment period. For patients who fail to complete the study, adherence will be estimated as the number of doses they report taking for visits at which they are present over the total number of doses they should have received. | 36 weeks |
| To assess the safety, tolerability, and acceptability of the intervention with formoterol | Rates of adverse events and safety measures will be compared between groups. The investigators will assess adherence with the intervention and study medication. | 36 Weeks |
| To perform preliminary efficacy testing and determine the variability of albuminuria | Changes in albuminuria will be compared between groups to provide preliminary efficacy testing. | 36 Weeks |
| To perform preliminary efficacy testing and determine the variability of eGFR. | Changes in eGFR will be compared between groups to provide preliminary efficacy testing. eGFR will be assessed using the CKD-Epi Formula. | 36 Weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Safety Monitoring: Body Weight | Body weight will be measured using a digital scale accurate to +/- 0.1 kg at Screening, Week 0, Week 24, and Week 36. The investigator monitors changes in participants' body to detect any changes that may indicate treatment effects or safety concerns. | 36 Weeks |
| EKG Evaluations |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Recruitment Contact | Contact | (843) 792-0965 | recruitment@musc.edu |
| Name | Affiliation | Role |
|---|---|---|
| Joshua Lipschutz, MD | Medical University of South Carolina | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Medical University of South Carolina | Recruiting | Charleston | South Carolina | 29425 | United States |
Not provided
| ID | Term |
|---|---|
| D003928 | Diabetic Nephropathies |
| D003920 | Diabetes Mellitus |
| ID | Term |
|---|---|
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
An EKG will be performed at Screening, Week 0, Week 4, Week 16, Week 36, and Week 40. The investigators will be monitoring for new EKG changes suggestive of beta-adrenergic use such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression, and/or serum potassium <3.0 mEQ/L refractory to medical therapy. |
| 40 Weeks |
| Adherence | Adherence will be defined as the proportion of doses taken during the 36-week treatment period. For patients who fail to complete the study, adherence will be estimated as the number of doses they report taking for visits at which they are present over the total number of doses they should have received | 36 Weeks |
| Adverse Events | Rate of protocol related adverse events and serious adverse events will be compared between groups | 40 Weeks |
| Tolerability and acceptability | Intervention Tolerability: Participants will be asked every four weeks (Week 4-36) to rate on a 1-10 Likert scale how tolerable the intervention was over the past four weeks. Intervention Acceptability: Satisfaction with the intervention will be assessed every 4 weeks (Week 4-36) with a questionnaire that asks participants to rate on a 1-10 Likert scale how satisfied they were with specific domains of the intervention over the past 4 weeks. The major domains that will be assessed are satisfaction with: 1) how hard was it to adhere to prescribed treatment, and 2) how likely they feel they can adhere to the prescribed treatment for the next four weeks. Participants will also be asked in open-ended fashion to provide feedback on each domain of the intervention. The investigators will also assess intervention acceptability by comparing the frequency of protocol related adverse events, requirement for protocol modification, and attrition between groups. | 32 Weeks |
| Liver Ultrasound Elastography | non-invasive liver ultrasound elastography to determine if the patients had an improvement in liver steatosis with formoterol | 36 Weeks |
| Laboratory Evaluations: HbA1c | HbA1c assessments at Screening, Week 0, Week 16, Week 36, and Week 40 will be estimated and compared between and within groups. | 40 Weeks |
| Laboratory Evaluations: CMP | Comprehensive Metabolic Panel (CMP) (including hypokalemia assessments) at Screening, Week 0, Week 4, Week 12, Week 24, Week 36, and Week 40 will be estimated and compared between and within groups. | 40 Weeks |
| Laboratory Evaluations: Urine Albumin | Change in albuminuria between groups from baseline to the end of the study | 40 Weeks |
| Laboratory Evaluations: eGFR | Change in estimated glomerular filtration rate (eGFR, CKD-Epi eGFR formula) between groups from baseline to the end of the study | 40 Weeks |
| Safety Monitoring: Heart Rate | The investigator monitors changes in participants' heart rate throughout the trial to detect any changes that may indicate treatment effects or safety concerns. | 40 Weeks |
| Safety Monitoring: Blood Pressure | The investigator monitors changes in participants' blood pressure throughout the trial to detect any changes that may indicate treatment effects or safety concerns. Blood pressure (BP) will be measured with a sphygmomanometer (average of 2 seated values taken after five minutes of rest). | 40 Weeks |
| Safety Monitoring: Respiratory Rate | The investigator monitors changes in participants' respiratory rate throughout the trial to detect any changes that may indicate treatment effects or safety concerns. | 40 Weeks |
| Safety Monitoring: Temperature | The investigator monitors changes in participants' temperature throughout the trial to detect any changes that may indicate treatment effects or safety concerns. | 40 Weeks |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D048909 | Diabetes Complications |
| D004700 | Endocrine System Diseases |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |